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The pathophysiology of brain damage that is common to ischemia–reperfusion injury and
brain trauma include disodered neuronal and glial cell energetics, intracellular acidosis,
calcium toxicity, extracellular excitotoxic glutamate accumulation, and dysfunction of the
cytoskeleton and endoplasmic reticulum. The principal thyroid hormones, 3,5,3′-triiodo-L-
thyronine (T3) and L-thyroxine (T4), have non-genomic and genomic actions that are relevant
to repair of certain features of the pathophysiology of brain damage.The hormone can non-
genomically repair intracellular H+ accumulation by stimulation of the Na+/H+ exchanger
and can support desirably low [Ca2+]i.c. by activation of plasma membrane Ca2+–ATPase.
Thyroid hormone non-genomically stimulates astrocyte glutamate uptake, an action that
protects both glial cells and neurons. The hormone supports the integrity of the microﬁla-
ment cytoskeleton by its effect on actin. Several proteins linked to thyroid hormone action
are also neuroprotective. For example, the hormone stimulates expression of the seladin-1
gene whose gene product is anti-apoptotic and is potentially protective in the setting of
neurodegeneration.Transthyretin (TTR) is a serum transport protein forT4 that is important
to blood–brain barrier transfer of the hormone and TTR also has been found to be neuro-
protective in the setting of ischemia. Finally, the interesting thyronamine derivatives of T4
have been shown to protect against ischemic brain damage through their ability to induce
hypothermia in the intact organism. Thus, thyroid hormone or hormone derivatives have
experimental promise as neuroprotective agents.
Keywords: thyroid hormone, thyronamines, sodium-proton exchanger, calcium ATPase, seladin-1, transthyretin,
ischemia–reperfusion injury
INTRODUCTION
The critical contributions of thyroid hormone to development
of the nervous system (Farwell et al., 2006; Bernal, 2007), to
mature and immature brain glial cell (Siegrist-Kaiser et al., 1990;
Farwell et al., 1995, 2006), and neuronal function (Yonkers and
Ribera, 2008; Zhou et al., 2011) and to behavior (Davis et al.,
2010) are well-known. While hypothyroidism has been reported
by some observers to be neuroprotective in the setting of ischemia
(Shuaib et al., 1994a; Alevizaki et al., 2006), repeated admin-
istration of l-thyroxine (T4) has also been shown to protect
against brain ischemia (Rami and Krieglstein, 1992) and thy-
roid hormone is known to support the integrity of brain vas-
culature (Schlenker et al., 2008). Iodothyronines may support
by non-genomic or genomic molecular mechanisms support the
activities of plasma membrane ion pumps or channels that are
important to normal excitable cell function. These pumps that
are stimulated by 3, 5, 3′-triiodo-l-thyronine (T3) or, in some
cases, by T4 include the Na+/H+ exchanger (Incerpi et al., 1998),
Na, K-ATPase (Lei et al., 2004, 2006), and Ca2+-ATPases (Davis
et al., 1983a,b; Mylotte et al., 1985) and the channels include
the inward rectiﬁer K+ channel (Sakaguchi et al., 1996) and the
Na+ current (Yonkers and Ribera, 2008; Zhou et al., 2011). A
contribution to normalizing intracellular pH in the setting of
excess H+ accumulation (Incerpi et al., 1998) that occurs with
ischemia/acidosis is obviously a desirable action of the hormone,
as would be stimulation of Na, K-ATPase that would main-
tain normal [Na+]i.c. in the face of enhanced proton-for-Na+
exchange. Thyroid hormone can also increase glial cell gluta-
mate uptake (Mendes-de-Aguiar et al., 2008), thus protecting
neurons and astrocytes against the toxicity of glutamate at the
cell surface.
In this review, we will brieﬂy describe the molecular basis
for several actions of thyroid hormone analogs that can now
be interpreted as neuroprotective. Most of these actions are
non-genomic in mechanism, that is, they do not rely primar-
ily on the interaction of T3 with nuclear thyroid hormone
receptors (TR proteins) and consequent speciﬁc gene tran-
scription (Cheng et al., 2010). The hormones are T3, T4, and
the thyronamines (Piehl et al., 2011). We will also comment
on the apparently neuroprotective action of a serum thyroid
hormone transport protein, transthyretin (TTR; Santos et al.,
2010).
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GLUTAMATE NEUROTOXICITY AND THYROID HORMONE
Increases in extraneuronal glutamate neurotransmitter concentra-
tion stimulate nerve cell glutamate receptors and can result in exci-
totoxicity and neuronal death (Danbolt, 2001; Mendes-de-Aguiar
et al., 2008). Via several high afﬁnity glutamate-speciﬁc trans-
porters, astrocytes take up glutamate from the extracellular matrix
environment and are a defense against neuronal excitotoxicity.
Within the cell, glutamate supports several metabolic cascades,
including energy production and antioxidant (glutathione) func-
tions. The brain damage that results from ischemia is mediated to
an important degree by excessive glutamate release from neurons
and glial cells (see review by Mongin, 2007), resulting in excessive
depolarization and accumulation of cytoplasmic Ca2+. In addi-
tion to glutamate and calcium toxicity, other factors contributing
to neuronal damage and death in ischemia include free radical and
nitric oxide accumulations and dysfunction of mitochondria and
endoplasmic reticulum (Guo et al., 2009).
Against this background, studies by Mendes-de-Aguiar et al.
(2008) reported that T3 at 10−8 M eliminated the“gliotoxic” effect
of glutamate on cultured cerebellar astrocytes from newborn rats
and ensured viability of astrocytes and of neurons co-cultured
with the astrocytes. The mechanism involved in these observa-
tions included increased astrocyte uptake of glutamate that was
attributable to increased cellular abundance of GLT-1 and GLAST
mRNAs and protein. GLT-1 and GLAST are the principal plasma
membrane glutamate transporters of astrocytes. Losi et al. (2008)
showed that T3 protected rat hippocampal neurons against glu-
tamate toxicity by a non-genomic mechanism). Thus, the defense
against glutamate toxicity in neurons and glial cells that is imposed
by T3 may be both genomic and non-genomic in mechanism.
The existence of seamless interfaces between thyroid hormone-
initiated non-genomic and genomic actions has recently been
appreciated (Lin et al., 2009; Cheng et al., 2010; Davis et al., 2011).
Given the contributions of excessive glutamate accumulation
extraneuronally to ischemic brain injury, brain concussive injury
(Yi and Hazell, 2006; Jennings et al., 2008), heavy metal tox-
icity (Struzyriska, 2009), and a variety of other brain damage
syndromes, there is a rationale for investigating the feasibility
of modulating glutamate toxicity with thyroid hormone analogs.
Depending upon the pathological setting and model, the sched-
uling of hormone administration may be acute or subacute. It
may be useful to quantitate the proportion of the hormonal effect
in models that is non-genomic in initiation and thus subject to
management with T3 that has been reformulated to act at the cell
surface (Lin et al., 2011).
HYPOTHYROIDISM AND NEUROPROTECTION; THYROID
HORMONE ADMINISTRATION AND NEUROPROTECTION
Because both hypothyroidism and thyroid hormone administra-
tion have been reported to be protective in the setting of brain
ischemia, it is important to specify the experimental conditions
under which these actions have been described. Experimental
hypothyroidism (Shuaib et al., 1994a; Rastogi et al., 2006) and
subclinical hypothyroidism (Alevizaki et al., 2006;Akhoundi et al.,
2011) may result in apparently improved neurological outcomes
from brain ischemia, that is, preservation of function. The experi-
mental hypothyroidismobservations have been collected in several
animal models of transient cerebral ischemia in which the state
of established hypothyroidism has either reduced neuronal death
(Shuaib et al., 1994a; Rastogi et al., 2006) or has delayed, but
did not prevent, neuronal death (Lee et al., 2010). The rationales
for an apparently protective effect of thyroid hypofunction estab-
lished prior to neurological insult include decreased metabolic
demands of nerve cells, decreased oxidative stress (Rastogi et al.,
2006), decreased excitatory glutamate production (Shuaib et al.,
1994b), and, possibly, decreased body temperature. Decreased glu-
tamate production per se can be viewed as neuroprotective in the
sense of attenuated excitotoxicity (see below), however, it may
not be desirable when it impairs antioxidant glutathione produc-
tion (Mendes-de-Aguiar et al., 2008). It is presently impractical
clinically to induce hypothyroidism acutely, although, as will be
described below, the thyronamine thyroid hormone analogs can
induce hypothermia quickly and neuroprotection may be afforded
by this measure.
Reduction of hippocampal neuronal damage from ischemia
with repeateddailyT4 administrationwas shown in the rat 20 years
ago by Rami and Krieglstein (1992), with approximately a 50%
increase in neuronal density attributable to hormone treatment.
Subsequently, it was shown that experimental hyperthyroidism
that is established before focal ischemia may increase neuronal
insult in the rat (Rastogi et al., 2008). Thus, any neuronal res-
cue that may occur with thyroid hormone administration must
avoid induction of hypermetabolism. The molecular basis for an
acute effect of thyroid hormone isoforms on post-ischemic neu-
ronal survival may involve on genomic actions of the hormone
on intracellular pH, Na+, and Ca2+, as suggested above. T3 has
been shown to stimulate Na+/H+ (NHE1) exchanger/transporter
activity in excitable cells and to enhance recovery of intracellu-
lar pH after an acid load (Incerpi et al., 1998). The mechanism of
increased exchanger activity includes thyroid hormone-dependent
activation of mitogen-activated protein kinase (MAPK; D’Arezzo
et al., 2004). The ischemic neuron has accumulated H+ and thus
enhanced exchanger pump activity is desirable from the stand-
point of pH. The theoretical price that is paid for increased
Na+/H+ activity is the import of Na+, the consequent possibil-
ity of reverse Na+/Ca2+ exchange (NSCE) and an undesirable
increase in [Ca2+]i.c.. However, T3 also stimulates Na, K-ATPase
activity (Lei et al., 2004, 2006), and increases the number of pump
subunits inserted in the plasma membrane. This effect acts to
reduce [Na+]i.c.. Finally, a number of studies have shown iodothy-
ronines activate Ca2+-ATPase activity (Davis et al., 1983a; Mylotte
et al., 1985) by a calmodulin-dependent mechanism (Davis et al.,
1983b); this non-genomic effect contributes to modulation of any
increase in intracellular Ca2+ that may occur.
Given that iodothyronines can increase certain membrane
ion pump activities, it seems paradoxical that overall neu-
ronal excitability – spike number and action potentials – might
be decreased by the hormone. We have already described the
inhibitory effect of T3 on glutamate excitotoxicity that affects neu-
rons and appears to be mediated by glial cells. In addition, Cao
et al. (2011) have recently reported a non-genomic effect of T4 to
decrease the excitability of pyramidal neurons of prefrontal cortex
slices.While this is potentially an energy-conservingmechanism at
a time of hypoxic stress, the observation requires conﬁrmation and
Frontiers in Molecular Neuroscience www.frontiersin.org October 2011 | Volume 4 | Article 29 | 2
Lin et al. Thyroid hormone and neuroprotection
studies of mechanism, since thyroid hormone is known increase
certain membrane ion currents (Sakaguchi et al., 1996; Yonkers
and Ribera, 2008; Zhou et al., 2011).
In summary, the decreased metabolic demands of the hypothy-
roid brain may reduce the impact of ischemia. However, acute
imposition of hypothyroidism in the clinical context of CNS
ischemia is impractical. Protection of intraneuronal or glial pH,
and [Ca2+]i.c. and suppression of glutamate neuroexcitation (see
below) with a short-term, non-hyperthyroid increase in iodothy-
ronines appears to deserve further experimental evaluation in
euthyroid animal models of ischemia/stroke. Certain of the neu-
roprotective actions of thyroid hormone are depicted in Figure 1.
SELADIN-1 AND AMYLOID-β PROTEIN PRECURSOR AND
THYROID HORMONE
The SELective AD Indicator-1 (seladin-1) gene codes for a novel
protective factor that has been seen to be deﬁcient in Alzheimer’s
disease (AD; Greeve et al., 2000; Peri and Serio, 2008). Among
several effects, the protein inhibits pro-apoptotic caspase 3. The
seladin-1 protein also has enzymatic activity as a hydroxysterol
reductase that converts desmosterol to cholesterol. Thyroid hor-
mone, particularly T3, promotes the expression of seladin-1 in
neuronal precursor cells, such as human mesenchymal stem cells
and fetal neuroepithelial cells (Benvenuti et al., 2008). Thus, the
actions of thyroid hormone on the seladin-1 axis are relevant
to brain cell development/differentiation and appear to protect
neuron precursor cells from programmed cell death. The critical
FIGURE 1 | Selected mechanisms at the plasma membrane by which
thyroid hormone may non-genomically or genomically have protective
effects on neurons and glial cells in the setting of acute brain ischemia.
In response to thyroid hormone (T3), astrocytes and neurons may take up
glutamate from the extracellular apace via increased activity of speciﬁc
transporters (GLAST and GLT-1), reducing neuroexcitation fostered by
glutamate at the neuronal surface. The hormone may also increase the
number of glutamate transporters in the plasma membrane. Thyroid
hormone (T3) increases activity of the Na/H exchanger, reducing the
intracellular acid load that results from ischemia. Sodium pump (Na,
K-ATPase) activity is enhanced byT3 and there is increased expression of
the Na, K-ATPase gene in response to iodothyronines. Export of Na+ by the
pump is relevant because of the increased activity of the Na/H exchanger
results in import of Na+. An increase in [Na+]i.c. results in an undesirable
increase in cell uptake of Ca2+ by sodium–calcium exchange (not shown in
the ﬁgure). Enhanced activity of the calcium pump (Ca2+-ATPase) caused by
thyroid hormone (T4 andT3) also protects against intracellular accumulation
of Ca2+. ECM, extracellular matrix.
contributions of thyroid hormone to embryonic-fetal brain devel-
opment are very well-recognized and now may include contri-
butions from seladin-1 gene expression. The optimistic possibility
may also exist that seladin-1 is a factor that supports a pool of mul-
tipotent CNS cells beyond the period of brain development and
that might be accessed in the settings of certain brain disorders.
In addition to stimulating expression of seladin-1, T3 is known
to suppress expression of the β-amyloid precursor protein (APP)
gene in neuroblastoma cells in vitro (Belandia et al., 1998). The
hormone had been reported earlier by the same group to have
complex and variable effects on APP gene splicing (Latasa et al.,
1998). Tan and Vasan (2009) have recently reviewed a substantial
literature on thyroid function in the setting of AD and have spec-
ulated that suboptimal iodothyronine concentrations in the CNS
may support AβPP accumulation and the products thereof, It is
not clear whether the amyloid-β-peptide and amyloid-β-protein
are etiologic or secondary factors in a complex pattern of patho-
genesis inAD. However, the possibility that thyroid hormone has a
neuroprotective effect in the context of neurodegeneration would
appear to warrant additional experimental consideration.
Such a consideration also raises the issue of transport of thy-
roid hormone isoforms from blood into brain tissue. At least in
part, such intercompartmental transport involves TTR, a serum
transport protein for T4 and for tetraiodothyroacetic acid (tetrac);
TTR is discussed below as a possible neuroprotective factor in
ischemia. In addition, and emphasizing the complexity of the rela-
tionship of TTR to neuroprotection and neurodegenertation,TTR
has been reported to have apparently contradictory actions in the
mouse model of AD, in that it may enhance cleavage of the Aβ-
peptide (Costa et al. (2006)) and accelerate vascular deposition of
Aβprotein (Wati et al., 2009). This controversy requires resolution.
TRANSTHYRETIN IN BRAIN ISCHEMIA
Transthyretin, is a blood andCSFprotein that contributes tomain-
taining intravascular pools of T4 and of retinol. As noted above,
TTR is also responsible for facilitating access of thyroid hormone
to brain. TTR is secreted by the liver and by choroid plexus. It is
involved in amyloid deposition. Because brain TTR gene expres-
sion is increased in response to injury/ischemia,Santos et al. (2010)
recently searched for a possible contribution of TTR to neuropro-
tection. The investigators were surprised to ﬁnd that the brain
of the TTR null mouse did not exhibit increased vulnerability
to ischemic damage. However, when a mouse heterozygous for
heat-shock transcription factor 1 (HSF1) – and thus exhibiting a
somewhat impaired stress response was rendered TTR−/−, mid-
dle cerebral artery occlusion induced a profoundly severe injury
in terms of volume of brain cortex infarct, cerebral edema, and
white blood cell immigration. The increase in severity of dam-
age was expressed relative to that in the TTR+/+ HSF1+/− control
animals. Interestingly, TTR, itself, was distributed throughout the
area of infarction in the TTR−/− HSF1+/− mouse brain. Thus,
TTR can be neuroprotective, but this is apparent only when a sec-
ond stress or defense factor is impaired and such is the case in the
HSF1+/− mouse brain in the setting of ischemia. In these studies,
it was CSF-source TTR that was important to neuroprotection,
since inhibition by RNAi of liver TTR production did not affect
the model.
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The results emphasize that there may be redundancy in neuro-
protective responses that are based on proteins such as TTR and
HSF1 and this has implications for experimental design. The study
does not provide insight into possible contributions of thyroid
hormone-binding or retinol-binding (or retinol-binding globu-
lin) to the behavior of TTR in the neuroprotective response. This
issue is of some relevance, given the preceding discussion of neu-
roprotective actions of thyroid hormone isoforms, themselves, on
local accumulations of glutamate or on intracellular pH of glial
cells or neurons.
THYRONAMINES, HYPOTHERMIA, AND NEUROPROTECTION
Thyronamines are thyroid hormone derivatives whose side chain
has been decarboxylated. Two thyronamines – the completely
deiodinated product (T0AM) and a derivative that retains the
3-iodine (T1AM) – have been exploited for several experimen-
tal purposes by Scanlan and colleagues (Piehl et al., 2011) and
are of particular interest with regard to brain protection. The
compounds occur naturally in small quantities and are ligands
for a G protein-coupled receptor (TAAR1), rather than for TRs.
One of their remarkable effects is that of lowering body temper-
ature without inducing homeostatic responses. Because of the
known protective effect of hypothermia on brain damage asso-
ciated with ischemia, the thyronamines have been tested by Doyle
et al. (2007) against stroke injury. Administered intraperitoneally
1 h after middle cerebral artery occlusion, the agents promptly
lowered mouse body temperature to 31˚C from 37˚C. The thy-
ronamines signiﬁcantly reduced brain infarct volume at 24 h by
about 33%. The speciﬁcity of the neuroprotective impact of hor-
mone analog-induced hypothermia was shown by prevention of
the neuronal salvage by maintaining animal body temperature at
37˚C during administration of thyronamines. The induction of
hypothermia by the thyronamines is presumed to be mediated by
the TAAR1 receptor and the nerve cell salvage is thought to reﬂect
decreased metabolic rate and lowered free radical generation.
The apparent effectiveness of the agents in ischemia-induced
brain injury does not exclude consideration of the thyronamines
for application to other models of CNS injury, for example, con-
cussive trauma and global anoxic damage at the time of cardiac
arrest. It is clear that systemic administration of the thyronamines
permits their trespass of the blood–brain barrier, but it is not
known by what precise mechanism the barrier is crossed. The thy-
ronamines do not appear to gain access to the interior of cells by
the principal thyroid hormone uptake system, monocarboyxlate
transporter 8 (MCT8; Kinne et al., 2010).
POSSIBLY PROTECTIVE EFFECTS OF T4 ON GLIAL CELL
CYTOSKELETON AND INTRACELLULAR PROTEIN
TRAFFICKING
Thyroid hormone, notably T4, has important actions on the
actin cytoskeleton that were ﬁrst described in glial cells in 1990
(Siegrist-Kaiser et al., 1990). Interestingly, reverse T3, but not T3,
also stabilizes the cytoskeleton (Farwell et al., 2006). Under the
direction of thyroid hormone, soluble actin is converted to F-
actin in a variety of cells, a function that stabilizes microﬁlaments,
enabling cell motility, and the interaction of cells with extracellu-
lar proteins. The latter include laminins that support adhesion to
the basal lamina (basement membrane) and growth factors that
are neuroprotective, such as basic ﬁbroblast growth factor (bFGF)
and epidermal growth factor (EGF; Hicks et al., 1998). Dissolu-
tion of the cytoskeleton is one phase of ischemic neuronal cell
death (Lipton, 1999) and thus, thyroid hormone may be a fac-
tor that desirably stabilizes cell and tissue structure in the face of
ischemic challenge to structure. Iodothyronines have been shown
to enhance activities of EGF (Lin et al., 1999) and bFGF (Davis
et al., 2004).
The cytoskeleton is also important to cell protein trafﬁck-
ing, a process whose maintenance is imperative in response to
ischemia/hypoxia. Thyroid hormone has very substantial effects
on the intracellular trafﬁcking of kinases, nuclear hormone recep-
tors (cytoplasm-to-nucleus), and a variety of transactivators (Cao
et al., 2009; Davis et al., 2011). The energetics of the hypoxic cell
may be impaired and this may limit the activation of MAPK and
phosphatidylinositol 3-kinase by iodothyronines (Lin et al., 2009;
Davis et al., 2011) that is critical to trafﬁcking.
CONCLUSION
Thyroid hormone has a broad spectrum of actions on the nervous
system. These relate to brain development andmorphogenesis and
to a variety of brain functions and to behaviors of the intact organ-
ism. The molecular basis for such actions include modulation of
expression of speciﬁc genes, regulation of energetics in the mito-
chondrion and a variety of non-genomic actions on ion transport
systems, on the cytoskeleton, intracellular protein trafﬁcking, on
speciﬁc kinase activation and speciﬁc protein phosphorylation,
and on cell migration and angiogenesis; these multiple actions
have been reviewed by Cheng et al. (2010) and Davis et al. (2011).
That thyroid hormone may be neuroprotective has been explored
in this review. What is attractive about the apparently neuropro-
tective effect of T3 and T4 is that they coherently affect multiple
defense mechanisms that can be invoked in brain damage settings.
The possibility has also been discussed that thyroid hormone-
relevant proteins such as TTR may be defensive in the setting
of ischemia/reperfusion injury. Finally, the concept that thyroid
hormone analogs such as the thyronamines are relevant to neu-
roprotection should encourage exploration of additional forms of
the hormone for desirable effects on the nervous system at risk for
injury.
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